隶属于 cambridge isotope laboratories, inc.
相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
已完成
2
50.0%
招募中
2
50.0%
暂无批准数据
- Primo Biotechnology completed a NT$220 million Series A funding round, bringing total capital raised to over NT$500 million to accelerate radioligand theranostics development. - The Taiwan-based company obtained authorization from ABX to manufacture and distribute Radelumin ([18F]PSMA-1007) for prostate cancer diagnostics in Taiwan, beginning clinical supply in June 2025. - Primo is advancing pipeline candidates PB011 and PB012 through clinical trials while leveraging Taiwan's Category 2 registration pathway for faster market approval. - The company plans to launch its IPO in 2026 on Taiwan's TPEx Emerging Stock Board to expand R&D capabilities and international reach.
- Primo Biotechnology has formed a strategic partnership with Germany's ABX to introduce PB01, an advanced diagnostic radiotracer for prostate cancer, to the Taiwanese market amid rising disease incidence and mortality rates. - PB01, equivalent to Europe's approved Radelumin, utilizes PET/CT imaging technology to precisely detect Prostate Specific Membrane Antigen (PSMA) expression, enabling more accurate identification and monitoring of prostate cancer. - The collaboration aims to address Taiwan's urgent need for improved diagnostic tools, with Radelumin having already established itself as a valuable asset for early detection, staging, and recurrence monitoring in high-risk prostate cancer cases across Europe since 2021.
